Evaluation of Antagonistic Effects of Metformin with Cisplatin in Gastric Cancer Cells
-
Vahid Lesan
,
Seyed Hamidollah Ghaffari
,
Jamile Salaramoli
,
Mansour Heidari
,
Masoumeh Rostami
,
Kamran Alimoghaddam
,
Ardeshir Ghavamzadeh
Abstract
Metformin has recently been introduced as an anti-cancer agent. In this study, we evaluated the effect of metformin and metformin/cisplatin on human gastric MKN-45 cell line. When we used metformin alone, it could inhibit proliferation and induce apoptosis, but it diminish anti-proliferative effects of cisplatin when they are used in combination. Further, we checked mRNA levels of survivin, mTOR, and Akt by real-time PCR. When MKN-45 cells were treated with metformin/cisplatin, the expression of survivin and mTOR were increased. The antagonistic effect of metformin on cisplatin could be through survivin and mTOR signaling pathways. Our results also suggest that interfering effect of metformin on cisplatin may be also through upregulation of Akt. Regarding the pivotal role of Akt in drug resistance, it may be reasonable to conclude that the antagonistic effect of metformin on cisplatin effect may be through this central mediator of drug resistance. Taken together, it seems that metformin is not a good option for sensitizing MKN-45 cell line to cisplatin, and in co-prescription of metformin and cisplatin in gastric cancer patients who suffer diabetes type 2, it should be highly cared.
Basevi, V., et al., Comment on: American Diabetes Association. Standards of medical care in diabetes--2011. Diabetes Care 2011;34(Suppl. 1):S11-S61. Diabetes Care, 2011. 34(5): p. e53; author reply e54.
Moll, E., F. van der Veen, and M. van Wely, The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update, 2007. 13(6): p. 527-37.
Ravandi, F., et al., Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 2009. 27(4): p. 504-10.
Correia, S., et al., Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. Mini Rev Med Chem, 2008. 8(13): p. 1343-54.
Zhou, G., et al., Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001. 108(8): p. 1167-74.
Evans, J.M., et al., Metformin and reduced risk of cancer in diabetic patients. BMJ, 2005. 330(7503): p. 1304-5.
Chong, C.R. and B.A. Chabner, Mysterious metformin. Oncologist, 2009. 14(12): p. 1178-81.
Lee, M.S., et al., Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer, 2011. 11: p. 20.
Rattan, R., et al., Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia, 2011. 13(5): p. 483-91.
Wang, Y., et al., [Effects of antidiabetic drug metformin on human breast carcinoma cells with different estrogen receptor expressing in vitro]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 2011. 27(3): p. 253-6.
Inoki, K., T. Zhu, and K.L. Guan, TSC2 mediates cellular energy response to control cell growth and survival. Cell, 2003. 115(5): p. 577-90.
Buzzai, M., et al., Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res, 2007. 67(14): p. 6745-52.
Huang, X., et al., Important role of the LKB1–AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. Biochem J, 2008. 412(2): p. 211-221.
Jiralerspong, S., et al., Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer. Journal of Clinical Oncology, 2009. 27(20): p. 3297-3302.
Zhuang, Y. and W.K. Miskimins, Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal, 2008. 3: p. 18.
Zakikhani, M., et al., Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res, 2006. 66(21): p. 10269-73.
Parkin, D.M., International variation. Oncogene, 2004. 23(38): p. 6329-40.
Pruefer, F.G., et al., Participation of Omi Htra2 serine-protease activity in the apoptosis induced by cisplatin on SW480 colon cancer cells. J Chemother, 2008. 20(3): p. 348-54.
Jordan, P. and M. Carmo-Fonseca, Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci, 2000. 57(8-9): p. 1229-35.
Lin, C.C., et al., Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway. Am J Respir Cell Mol Biol, 2013. 49(2): p. 241-50.
Gotlieb, W.H., et al., In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol, 2008. 110(2): p. 246-50.
Janjetovic, K., et al., Metformin reduces cisplatin-mediated apoptotic death of cancer cells through AMPK-independent activation of Akt. Eur J Pharmacol, 2011. 651(1-3): p. 41-50.
Chang, J., et al., Protective Effect of Metformin Against Cisplatin-Induced Ototoxicity in an Auditory Cell Line. J Assoc Res Otolaryngol, 2013.
Scartozzi, M., et al., Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother, 2007. 8(6): p. 797-808.
Ikeguchi, M., J. Liu, and N. Kaibara, Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis, 2002. 7(1): p. 23-29.
Tamm, I., et al., IAP-Family Protein Survivin Inhibits Caspase Activity and Apoptosis Induced by Fas (CD95), Bax, Caspases, and Anticancer Drugs. Cancer Research, 1998. 58(23): p. 5315-5320.
Kato, J., et al., Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer, 2001. 95(2): p. 92-5.
Adida, C., et al., Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. The Lancet, 1998. 351(9106): p. 882-883.
Monzo, M., et al., A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol, 1999. 17(7): p. 2100-4.
Sarela, A.I., et al., Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut, 2000. 46(5): p. 645-50.
Vazquez-Martin, A., et al., The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Annals of Oncology, 2009. 20(3): p. 592-595.
Datta, S.R., et al., Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell, 1997. 91(2): p. 231-41.
Brunet, A., et al., Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell, 1999. 96(6): p. 857-68.
Zimmermann, S. and K. Moelling, Phosphorylation and regulation of Raf by Akt (protein kinase B). Science, 1999. 286(5445): p. 1741-4.
Cardone, M.H., et al., Regulation of cell death protease caspase-9 by phosphorylation. Science, 1998. 282(5392): p. 1318-21.
Romashkova, J.A. and S.S. Makarov, NF-[kappa]B is a target of AKT in anti-apoptotic PDGF signalling. Nature, 1999. 401(6748): p. 86-90.
Yuan, T.L. and L.C. Cantley, PI3K pathway alterations in cancer: variations on a theme. Oncogene, 2008. 27(41): p. 5497-510.
Hayakawa, J., et al., Inhibition of BAD Phosphorylation Either at Serine 112 via Extracellular Signal-regulated Protein Kinase Cascade or at Serine 136 via Akt Cascade Sensitizes Human Ovarian Cancer Cells to Cisplatin. Cancer Research, 2000. 60(21): p. 5988-5994.
Winograd-Katz, S.E. and A. Levitzki, Cisplatin induces PKB//Akt activation and p38MAPK phosphorylation of the EGF receptor. Oncogene, 2006. 25(56): p. 7381-7390.
| Files | ||
| Issue | Vol 8, No 3 (2014) | |
| Section | Articles | |
| Keywords | ||
| Akt Cisplatin Gastric cancer Metformin Survivin mTOR | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
